Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry
- PMID: 18596579
- DOI: 10.1203/PDR.0b013e318183f132
Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry
Abstract
Fabry disease is an X-linked lysosomal disease caused by deficiency of alpha-galactosidase A. Signs and symptoms of Fabry disease occurring during childhood and adolescence were characterized in 352 Fabry Registry patients. At enrollment (median age 12 year), 77% of males and 51% of females reported symptoms. The median age of symptom onset was 6 year in males and 9 year in females. The most frequent symptom, neuropathic pain, was reported by 59% of males (median age 7 year) and 41% of females (median age 9 year). Gastrointestinal symptoms were reported by 18% of children (median age 5 year in males and 9.5 year in females). Males exhibited height and weight values below the US 50th percentile. Females had weight values above the US 50th percentile. A few patients had serious renal and cardiac manifestations, stage 2 or 3 chronic kidney disease (n = 3), arrhythmia (n = 9), and left ventricular hypertrophy (n = 3). Thus, many pediatric Fabry patients report early symptoms, particularly pain, gastrointestinal symptoms, and impaired quality of life. Some children experience major complications during the pediatric years.
Similar articles
-
Pediatric Fabry disease.Pediatrics. 2005 Mar;115(3):e344-55. doi: 10.1542/peds.2004-1678. Epub 2005 Feb 15. Pediatrics. 2005. PMID: 15713906
-
End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.Nephrol Dial Transplant. 2010 Mar;25(3):769-75. doi: 10.1093/ndt/gfp554. Epub 2009 Oct 21. Nephrol Dial Transplant. 2010. PMID: 19846394
-
Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.Nephrol Dial Transplant. 2008 May;23(5):1600-7. doi: 10.1093/ndt/gfm848. Epub 2008 Jan 5. Nephrol Dial Transplant. 2008. PMID: 18175781
-
Fabry disease: molecular genetics of the inherited nephropathy.Adv Nephrol Necker Hosp. 1989;18:113-27. Adv Nephrol Necker Hosp. 1989. PMID: 2564247 Review.
-
Early therapeutic intervention in females with Fabry disease?Acta Paediatr. 2008 Apr;97(457):41-7. doi: 10.1111/j.1651-2227.2008.00649.x. Acta Paediatr. 2008. PMID: 18339187 Review.
Cited by
-
Left to themselves: Time to target chronic pain in childhood rare diseases.Neurosci Biobehav Rev. 2021 Jul;126:276-288. doi: 10.1016/j.neubiorev.2021.03.008. Epub 2021 Mar 24. Neurosci Biobehav Rev. 2021. PMID: 33774086 Free PMC article. Review.
-
Brazilian consensus recommendations for the diagnosis, screening, and treatment of individuals with fabry disease: Committee for Rare Diseases - Brazilian Society of Nephrology/2021.J Bras Nefrol. 2022 Apr-Jun;44(2):249-267. doi: 10.1590/2175-8239-JBN-2021-0208. J Bras Nefrol. 2022. PMID: 35212703 Free PMC article.
-
Translation of quality of life scale for pediatric patients with Fabry disease in Japan.Mol Genet Metab Rep. 2022 Mar 3;31:100854. doi: 10.1016/j.ymgmr.2022.100854. eCollection 2022 Jun. Mol Genet Metab Rep. 2022. PMID: 35782618 Free PMC article.
-
Fabry disease - a multisystemic disease with gastrointestinal manifestations.Gut Microbes. 2022 Jan-Dec;14(1):2027852. doi: 10.1080/19490976.2022.2027852. Gut Microbes. 2022. PMID: 35090382 Free PMC article. Review.
-
α-Galactosidase A-deficient rats accumulate glycosphingolipids and develop cardiorenal phenotypes of Fabry disease.FASEB J. 2019 Jan;33(1):418-429. doi: 10.1096/fj.201800771R. Epub 2018 Jul 6. FASEB J. 2019. PMID: 29979634 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical